CORT Corcept Therapeutics Incorporated

12.99
+0.33  (+3%)
Previous Close 12.66
Open 12.77
Price To Book 4.96
Market Cap 1,476,817,993
Shares 113,688,837
Volume 651,125
Short Ratio
Av. Daily Volume 638,408

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved February 17, 2012.
Corlux - Korlym
Cushing's Syndrome
Phase 1/2 presented at ASCO June 3, 2019.
Relacorilant plus Abraxane
Solid tumors - cancer
Phase 3 commencement of enrolment announced November 19, 2018.
Relacorilant
Cushing’s syndrome
Phase 2 trial ongoing - noted May 9, 2019.
Relacorilant plus Abraxane
Ovarian cancer
Phase 2 trial to be initiated in 2020.
CORT118335
Nonalcoholic steatohepatitis (NASH)
Phase 1/2 dosing ongoing - May 9, 2019.
CORT125281 plus Xtandi
Castration-resistant prostate cancer (CRPC)
Phase 1b data due later in 2019.
CORT118335
Prevention of antipsychotic-induced weight gain
Phase 2 trial to be initiated 2H 2019.
CORT118335
Reversal of antipsychotic-induced Weight Gain (AIWG)
Phase 3 trial planned.
Relacorilant plus nab-paclitaxel
Pancreatic cancer

Latest News

  1. Edited Transcript of CORT earnings conference call or presentation 1-Aug-19 9:00pm GMT
  2. Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2
  3. Corcept Therapeutics Incorporated (CORT) Q2 Earnings Call Transcript
  4. Corcept Therapeutics (CORT) Q2 Earnings Beat Estimates
  5. Corcept Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update
  6. Does Corcept Therapeutics Incorporated (NASDAQ:CORT) Have A High Beta?
  7. Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
  8. Can We See Significant Insider Ownership On The Corcept Therapeutics Incorporated (NASDAQ:CORT) Share Register?
  9. Corcept Therapeutics Incorporated (NASDAQ:CORT): Poised For Long Term Success?
  10. Corcept (CORT) Down 11.3% Since Last Earnings Report: Can It Rebound?
  11. The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace
  12. Is Corcept Therapeutics Incorporated's (NASDAQ:CORT) P/E Ratio Really That Good?
  13. Corcept Therapeutics to Present Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting
  14. Lawsuit for Investors in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) announced by Shareholders Foundation
  15. Edited Transcript of CORT earnings conference call or presentation 9-May-19 9:00pm GMT
  16. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Corcept, Mobile TeleSystems, Healthcare Services, and American Renal and Encourages Investors to Contact the Firm
  17. CRBP, NIO & CORT Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Class Action
  18. DEADLINE MONDAY REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  19. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, HCSG, BA and NOK